Al-Razi Medical (9572) Fundamentals 2026 — P/E 55.4x, Revenue Analysis | SniperIQ
Al-Razi Medical (9572) is a SA-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of SAR 45M, trading at SAR 29.68 on the SAU. This SniperIQ fundamentals page covers Al-Razi Medical's valuation (P/E 55.4x, P/B 1.9x), profitability (net margin 1.1%), revenue (SAR 74M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Al-Razi Medical's market cap?
Al-Razi Medical (9572) has a market capitalization of approximately SAR 45M, trading at SAR 29.68 on the SAU. Market cap moves with the live share price.
What is Al-Razi Medical's P/E ratio?
Al-Razi Medical's trailing twelve-month P/E ratio is 55.4x, with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Al-Razi Medical?
Al-Razi Medical runs a net profit margin of 1.1%, a gross margin of 25.9%, and an operating margin of 2.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Al-Razi Medical generate?
Al-Razi Medical reported revenue of SAR 74M for fiscal year 2025, with net income of SAR 819,462 and earnings per share (EPS) of 0.54. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Al-Razi Medical pay a dividend?
Al-Razi Medical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Al-Razi Medical financially healthy?
Al-Razi Medical carries a debt-to-equity ratio of 0.51x and a current ratio of 1.47x, with a market beta of 0.31. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Al-Razi Medical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Al-Razi Medical (9572) the key facts are: market cap SAR 45M, P/E 55.4x, revenue SAR 74M, 52-week range 25.1-45.7. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Al-Razi Medical's full fundamentals live
Get Al-Razi Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.